KORU Medical Systems to Participate in the Canaccord Genuity 46th Annual Growth Conference

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”),a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will participate in the Canaccord Genuity 46thAnnual Growth Conference on August 12th, 2026.

KORU Medical's management is scheduled to present at the Canaccord Genuity 46thAnnual Growth Conference on August 12th, 2026, at 10:00 am ET.Interested parties can access the live and archived webcast on theNews/Eventspage of the Investors section of KORU Medical’s website atwww.korumedical.com.

KORU Medical develops, manufactures, and commercializes innovative and patient-centric subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the “Freedom System”) currently includes the Freedom60®and FreedomEDGE®Syringe Infusion Drivers, Precision Flow Rate Tubing™and High-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visitwww.korumedical.com.